AUPH - Aurinia Pharma's Lupkynis successful in late-stage lupus nephritis study

The Lancet has published the results of Aurinia Pharmaceuticals' (AUPH) Phase 3 AURORA 1 study evaluating Lupkunis (voclosporin) in adults with lupus nephritis ((LN)). AURORA 1 met its primary endpoint, achieving statistically superior complete renal response rates of 41% in the Lupkynis group versus 23% in the control group (odds ratio [OR] 2.65, 95% confidence interval [CI] 1.64-4.27; p < 0.0001).Lupkynis also achieved statistical significance in all pre-specified hierarchical secondary endpoints, including improved time to 50% reduction from baseline in UPCR or and time to UPCR <0.5 mg/mg compared to control.Lupkynis was well tolerated with no unexpected safety signals. Serious adverse events were reported in 21% of those treated with Lupkynis and in the control group, respectively.Overall mortality in the AURORA 1 trial was low, with six deaths observed; one in Lupkynis group and five in the control group.AUPH stock up 4.4% premarket trading at $10.59. Shares have plummeted ~24% over the past week

For further details see:

Aurinia Pharma's Lupkynis successful in late-stage lupus nephritis study